Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) containing non-proteinogenic residues and a C-terminal amide. Those modifications are analytically relevant: the unnatural residues change chromatographic behaviour and mean that a purity method validated for standard peptides may not resolve related-substance impurities correctly. Identity is confirmed by mass spectrometry against the calculated mass; purity is measured by reversed-phase HPLC with a stated gradient. All values on this record come from the supplier specification sheet and batch certificate of analysis.

Ipamorelin was described in the late 1990s during pharmaceutical work on growth hormone secretagogues, a class developed after the discovery of the growth hormone secretagogue receptor and, later, its endogenous ligand ghrelin. It was characterised as a selective secretagogue with a comparatively clean profile in preclinical models relative to earlier compounds in the class. Development did not proceed to a marketing authorisation, and the compound has no approved status in any jurisdiction.

Published work examines agonism at the growth hormone secretagogue receptor 1a, resulting pituitary growth hormone release in animal models and in early human pharmacology studies, and selectivity relative to ACTH, cortisol and prolactin release. Later work examined gastrointestinal motility endpoints, reflecting the receptor's role outside the pituitary. Studies report receptor binding parameters, hormone release kinetics and comparative selectivity against other secretagogues of the same era.

The receptor concerned has a substantial biology outside the pituitary, with expression reported in the gastrointestinal tract, pancreas and cardiovascular tissue, and the endogenous ligand ghrelin has documented effects on appetite, gastric motility and glucose handling. Published work on this compound examines selectivity in that broader context, which is the relevant question for a secretagogue: not only what is released, but what else the receptor does when it is engaged.

Receptor pharmacology is well characterised and reproduced across laboratories. Growth hormone release following administration in animal models is a consistent, dose-related finding. Selectivity relative to older secretagogues that also raised cortisol and prolactin is supported by comparative data in the original characterisation work and by subsequent studies. Early human pharmacology data on hormone release exist, which is more than can be said for most compounds in this class.

There are no completed randomised controlled trials establishing clinical efficacy for any indication; development stopped before that stage. Human data are limited to small pharmacology and postoperative-motility studies with short duration and modest participant numbers, and the motility work did not meet its endpoints. Nothing in the published record addresses long-term exposure, and no data characterise effects on IGF-1 over extended periods. Downstream physiological consequences of transient hormone release, as distinct from the release itself, are largely uninvestigated. Claims that circulate about body-composition outcomes are not supported by any controlled human trial.

It is also worth stating what discontinued development means as evidence. A compound that stops after early-phase work has not been shown to be ineffective; it has been shown to be unattractive to a sponsor, for reasons that may be commercial, strategic or scientific and are usually not published. That ambiguity cuts both ways, and it should not be resolved in the compound's favour by default. What remains verifiable is the receptor pharmacology and the hormone-release data, not any downstream benefit.

Store the lyophilised solid as stated in the storage conditions on this record, protected from light and moisture, with the sealed vial equilibrated to ambient temperature before opening. Amidated peptides with unnatural residues remain sensitive to humidity and to repeated freeze-thaw once in solution. This section describes laboratory handling of the material as supplied; it contains no preparation or administration procedure.

Indexed citations with verified PMIDs are listed below. Analytical methods behind the specification are described in testing methodology; batch documentation expectations are set out in sourcing standards. Related secretagogue records appear in the compound index.